Drug Profile
Research programme: therapeutic cancer vaccines - SQZ Biotech/Roche
Alternative Names: Antigen presenting cells - SQZ Biotech/Roche; APCs - SQZ Biotech/Roche; Next Gen SQZ APC; SQZ-PBMC-XLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Roche; SQZ Biotech
- Class Cancer vaccines; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 01 Feb 2022 Pharmacodynamics data from preclinical studies in Cancer released by SQZ Biotech
- 24 Mar 2021 Preclinical development is ongoing in USA (Parenteral) (SQA Biotech pipeline, March 2021)